New big generic


Reykjavik - Actavis Group, an international generic pharmaceuticals company operating from Iceland, is to acquire US-based Alpharma generic pharmaceuticals business for $810 million. The move will solidify Actavis' entry into the US generics market and comes shortly after the company's $600-million acquisition of Amide Pharmaceutical Inc., a private US generics company.
As a combined company Actavis seeks to be among the five largest players in generic pharmaceuticals worldwide. It will have more than 600 marketed products, as well as around 10,000 employees in 32 countries. Actavis expects to benefit from Alpharma's products that can be marketed in Actavis' existing markets and vice versa. The companys revenue in 2004 was Euro 452 million.



Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...



Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to...



Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...



Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...



Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...



Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues